The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

Women across social media platforms share their journeys of using Mucinex for fertility enhancement, spurring discussions ...

At the heart of this phenomenon lies guaifenesin, the active ingredient in Mucinex that typically works by breaking down and thinning mucus in the respiratory system. Women exploring alternative ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

Cold and flu sinus relief brand Mucinex took home the top monthly spot for TV ad impressions, dethroning long-time champion Vicks. Data released by iSpot.tv on Monday afternoon showed that the Reckitt ...

The nasal spray can be given to people who haven’t seen improvements to their depression after taking at least two oral medications, according to Johnson & Johnson. The main ingredient for the ...

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as the first and only monotherapy for adults with major depressive ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...